Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW – Get Free Report) was the target of a large increase in short interest during the month of July. As of July 15th, there was short interest totaling 146,438 shares, an increase of 3,848.2% from the June 30th total of 3,709 shares. Based on an average daily volume of 50,488 shares, the short-interest ratio is presently 2.9 days.
Rocket Pharmaceuticals Stock Performance
RCKTW stock opened at $0.00 on Friday. The business has a 50 day simple moving average of $0.01 and a 200-day simple moving average of $0.01. Rocket Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.08.
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.
Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.
Recommended Stories
- Five stocks we like better than Rocket Pharmaceuticals
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
